Abstract

Atrial Fibrillation (AF) is most common sustained cardiac arrhythmia. Catheter ablation is a therapy, which can be used in symptomatic patients refractory to antiarrhythmic treatment.Any ablation treatment still relies on Pulmonary vein isolation (PVI), which is fundamental. Even when the PVI is carried out in highly skilled institutions, PVI reconnection was observed in roughly 20% of patients, which highlights a significant shortcoming of existing catheter ablation methods. Therefore, better technology is required to enhance ablation lesions. One of the novel treatment is Pulsed Field Ablation (PFA), a non-thermal energy that uses trains of high-voltage, very-short-duration pulses to kill the cells. The mechanism of action of this energy consists of creating pores in the myocardiocyte cell membrane in a highly selective and tissue-specific way; this leads to death of the target cells reducing the risk of damage to surrounding non-cardiac tissues. It has been demonstrated that PFA does not harm esophageal tissue when administered directly to the esophagus or when administered inadvertently via ablation in the left atrium. The aim of this review is to report the confirming its safety and efficacy towards Atrial Fibrillation.

Description